Invitrogen

IL-6 Monoclonal Antibody (MP5-20F3), eBioscience™

Product Image Gallery

IL-6 Antibody — Figure 6. Microglia restricted ischemia-induced astrocyte response and neural injury. Primary cortical neurons were subjected to 5 min OGD. Immediately after OGD, culture media was replaced with regular neurobasal medium mixed with equal volume of glia-conditioned medium for 24 h. Glia-conditioned medium was obtained from cultured microglia, astrocytes or mixed microglia and astrocytes (microglia/astrocyte) at 24 h after 30 min OGD. (a) Representative images show staining of beta III Tubulin (green), DAPI (blue) and TUNEL (red) in primary cortical neurons exposed to OGD and glia-conditioned medium as indicated. Primary cortical neurons without exposure to OGD or glia-conditioned medium were used as controls. Scale bars: 20 um. (b) Quantification of TUNEL + cells after exposure to indicated treatment. CM: conditional medium. (c) Bar graphs show the level of released LDH from primary cortical neurons after exposure to indicated treatment. LDH release was expressed by normalizing the released LDH in the medium to the total LDH (released + intracellular). CM: conditional medium. (d) Primary astrocytes were cultured separately or together with microglia (microglia/astrocyte). After 30 min OGD and subsequent 24 h recovery, intracellular staining of GFAP and indicated cytokines was performed and analyzed by flow cytometry. Bar graphs show the percentage of GFAP + cells expressing IL-1alpha, IL-1beta, iNOS, CCL2, TNF-alpha and IL-6. Error bars represent SD.; * P < 0.05; ** P < 0.01.

IL-6 Antibody in ELISA (ELISA) — Mouse splenocytes (500,000 cells/ well) were activated with LPS (1 µg/mL) for 48 hours in Mouse IL-6 ELISPOT assay. Control well is medium alone.

Product Details

Tested Applications

Dilution

ELISA (ELISA)

0.5-2 µg/mL

Published Applications

ELISA (ELISA)

See 8 publications below

Flow Cytometry (Flow)

See 8 publications below

Functional Assay (FN)

See 2 publications below

Neutralization (Neu)

See 1 publication below

Product Specifications

Species Reactivity

Mouse

Published species

Mouse

Host / Isotype

Rat / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

MP5-20F3

Conjugate

Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

RRID

AB_468422

Product Specific Information

Description: The MP5-20F3 antibody reacts with mouse interleukin-6 (IL-6). The MP5-20F3 antibody is a neutralizing antibody. Mouse IL-6 (also known as B Cell Stimulating Factor, BCSF, and BSF-2) is a 21-28 kDa factor produced by a variety of cell types, including monocytes, fibroblasts and endothelial cells. Upon stimulation, macrophages, T, B, mast, and glial cells, eosinophils, keratinocytes and granulocytes also secrete IL-6. This pleiotrophic cytokine influences the antigen-specific immune response, inflammatory response, and the development of neurons, and is a major mediator of the acute phase reaction.

Applications Reported: This MP5-20F3 antibody has been reported for use in ELISA capture antibody and ELISPOT capture antibody.

Applications Tested: The MP5-20F3 antibody has been tested as the capture antibody in a sandwich ELISA for analysis of mouse Interleukin-6 (IL-6) in combination with the biotin MP5-32C11 (cat. 13-7062) antibody for detection and recombinant mouse IL-6 (cat. 14-8061) as the standard. A suitable range of concentrations of this antibody for ELISA capture is 0.5-2 µg/mL. A standard curve consisting of doubling dilutions of the recombinant standard over the range of 8-1000 pg/mL should be included in each ELISA plate.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

Interleukin 6 (IL-6) is a multifunctional 26 kD protein originally discovered in the medium of RNA-stimulated fibroblastoid cells. IL-6 appears to be directly involved in the responses that occur after infection and cellular injury, and it may prove to be important as IL-1 and TNF-a in regulating the acute phase response. IL-6 is reported to be produced by fibroblasts, activated T cells, activated monocytes or macrophages and endothelial cells. IL-6 acts upon a variety of cells including myeloid progenitor cells, T cells, B cells, and hepatocytes. In addition, IL-6 appears to interact with IL-2 in the proliferation of T lymphocytes. IL-6 potentiates the proliferative effect of IL-3 on multipotential hematopoietic progenitors. IL-6 plays a critical role in B-cell differentiation to plasma cells and is a potent growth factor for plasmacytoma and myeloma. IL-6 is a very useful culture supplement for the generation of a high number of antibody-producing hybridomas. Primarily produced at sites of acute and chronic inflammation, IL-6 is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of IL-6 is implicated in a wide variety of inflammation-associated disease states including diabetes mellitus and systemic juvenile rheumatoid arthritis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.